Bausch + Lomb Corporation Reports Strong Q2 Performance Amid Product Recall

Bausch + Lomb Corporation, a leading global eye health company, has announced its second-quarter 2025 results, showcasing a robust performance despite facing challenges such as a product recall. The company, which operates in the health care sector and trades on the Toronto Stock Exchange, reported a revenue of $1.278 billion. However, it also recorded a GAAP net loss attributable to the corporation of $62 million.

Despite the net loss, Bausch + Lomb demonstrated strong operational performance with an adjusted EBITDA (non-GAAP) of $191 million and an adjusted EBITDA excluding acquired IPR&D (non-GAAP) of $192 million. Revenue growth was reported at 5% as stated and 3% on a constant currency basis, indicating resilience in its core markets.

In a notable development, Bausch + Lomb has raised its full-year 2025 guidance, reflecting confidence in its strategic initiatives and market position. This optimistic outlook comes despite the backdrop of a product recall, which the company has managed to navigate effectively. The recall did not significantly hinder the company’s revenue growth, which accelerated, as reported by de.investing.com.

The company’s earnings per share (EPS) also exceeded estimates by $0.01, and its revenue performance was better than anticipated, as highlighted by de.investing.com. These financial metrics underscore Bausch + Lomb’s ability to maintain profitability and operational efficiency.

In addition to its financial results, Bausch + Lomb has made significant strides in its product pipeline. The company announced the publication of phase 3 data on LUMIFY® Preservative Free Redness Reliever Eye Drops, as reported by CEO.ca and Stockwatch.com. This development is expected to bolster the company’s product offerings and market competitiveness.

Bausch + Lomb’s parent company, Bausch Health Companies Inc., also reported strong consolidated revenues of $2.53 billion for the second quarter of 2025, marking a 5% increase on a reported basis and 4% on an organic (non-GAAP) basis over the prior year period. The parent company achieved a GAAP net income attributable to Bausch Health Companies of $148 million and a GAAP net income of $128 million.

Furthermore, Bausch Health announced its intention to acquire DURECT Corporation, a move aimed at strengthening its commitment to developing innovative solutions for patients with liver disease. DURECT’s lead asset, Larsucosterol, holds the potential to be the first FDA-approved therapeutic option for treating patients with alcoholic hepatitis, as noted by Finanznachrichten.de.

In a strategic financial move, Bausch Health also announced plans to reduce its debt by approximately $900 million using cash on hand, as reported by Finanznachrichten.de. This debt reduction is expected to enhance the company’s financial flexibility and support its long-term growth objectives.

Overall, Bausch + Lomb’s second-quarter results reflect a company that is not only navigating challenges effectively but also positioning itself for sustained growth and innovation in the eye health sector.